Pharmaceuticals

US Details Eligibility for Section 232 Specialty Pharmaceutical Tariff Exemptions

Yuvraj — Wed, 30 Sep 2026 12:37:44 +0000

The Trump administration has released detailed guidance regarding specialty pharmaceutical tariff exemptions for products including orphan treatments, nuclear medicines, cell and gene therapies, and antibody-drug conjugates (ADCs). Effective September 29, 2026, these rules allow specific drug classes to enter the United States duty-free, bypassing broad 100% Section 232 tariffs on patented pharmaceutical products and ingredients. […]

The post US Details Eligibility for Section 232 Specialty Pharmaceutical Tariff Exemptions first appeared on World Pharma Today.

FDA Releases Proposed Commitment Letter for Next Generic Drug User Fee Agreement

Yuvraj — Thu, 13 Aug 2026 12:31:11 +0000

Following months of negotiations with industry stakeholders, the US Food and Drug Administration (FDA) has published its proposed commitment letter for the GDUFA IV program. Announced in the Federal Register on Monday alongside details for an upcoming public meeting, the proposal introduces strategic initiatives to promote domestic manufacturing, implement a modernized meeting structure, and reduce […]

The post FDA Releases Proposed Commitment Letter for Next Generic Drug User Fee Agreement first appeared on World Pharma Today.

CPHI Launches New Sustainability Summit as Pharma Faces Growing Pressure to Deliver Sustainability Goals

Yuvraj — Thu, 13 Aug 2026 06:49:27 +0000

CPHI has announced the launch of the CPHI Sustainability Summit, a new two-day event dedicated to advancing sustainability across the pharmaceutical value chain. Taking place at Fiera Milano, Italy, on 5-6 October 2026, alongside CPHI Milan, the summit will bring together more than 300 sustainability leaders, pharmaceutical executives and supply chain stakeholders to discuss practical action on one of […]

The post CPHI Launches New Sustainability Summit as Pharma Faces Growing Pressure to Deliver Sustainability Goals first appeared on World Pharma Today.

Australia Reviews PBS Pricing Framework Amid Industry Dispute Over Benchmarks

Yuvraj — Fri, 17 Jul 2026 11:30:51 +0000

The Australian government is currently navigating a significant period of reassessment regarding its national drug reimbursement model, as tensions between global pharmaceutical manufacturers and health regulators reach a critical juncture. At the center of this dispute is the Pharmaceutical Benefits Scheme (PBS), a system that has long served as the primary mechanism for ensuring affordable […]

The post Australia Reviews PBS Pricing Framework Amid Industry Dispute Over Benchmarks first appeared on World Pharma Today.

Novartis and Antares Therapeutics Form Strategic Partnership for Cancer Drug Development

Yuvraj — Fri, 26 Jun 2026 07:23:30 +0000

Novartis has finalized a significant collaboration agreement with Antares Therapeutics to advance the discovery and development of small molecule therapies for various cancers. The deal, which could reach a total value of $1.9 billion, focuses on addressing oncology targets that have historically been categorized as undruggable. Under the terms of the agreement, Novartis will provide […]

The post Novartis and Antares Therapeutics Form Strategic Partnership for Cancer Drug Development first appeared on World Pharma Today.

Abu Dhabi and MSD Partner to Enhance Healthcare Access via New Logistics Hub

Yuvraj — Fri, 26 Jun 2026 05:12:11 +0000

The Department of Health – Abu Dhabi (DoH) has announced a strategic collaboration with MSD to evaluate the feasibility of establishing an Abu Dhabi logistics hub. Located within the Health, Endurance, Longevity, and Medicine (HELM) Cluster, this planned facility is designed to streamline the distribution of a comprehensive portfolio of pharmaceutical products across diverse regional […]

The post Abu Dhabi and MSD Partner to Enhance Healthcare Access via New Logistics Hub first appeared on World Pharma Today.

Bayer and Iambic Collaboration Expands AI Drug Discovery Efforts

Yuvraj — Thu, 25 Jun 2026 05:47:49 +0000

Bayer has strengthened its pharmaceutical and ophthalmology portfolio through two separate transactions, completing the acquisition of Perfuse Therapeutics while also entering a collaboration agreement with Iambic Therapeutics. The moves provide Bayer with full ownership of Perfuse’s lead asset, PER-001, and expand its access to advanced artificial intelligence technologies aimed at accelerating drug development. The acquisition […]

The post Bayer and Iambic Collaboration Expands AI Drug Discovery Efforts first appeared on World Pharma Today.

AbbVie Acquires Apogee in $10.9 Billion Healthcare Deal

Yuvraj — Wed, 24 Jun 2026 12:58:04 +0000

In a significant expansion of its research and development capabilities, a definitive agreement has been reached where AbbVie acquires Apogee Therapeutics for $10.9 billion. This strategic transaction is centered around the addition of zumilokibart, a highly anticipated IL-13 antibody, to the acquiring company’s expanding pipeline. By bringing this advanced asset in-house, the organization aims to […]

The post AbbVie Acquires Apogee in $10.9 Billion Healthcare Deal first appeared on World Pharma Today.

Moderna Commercial Expansion Accelerates Vaccine Launches

Yuvraj — Thu, 18 Jun 2026 10:26:16 +0000

Moderna is strengthening its commercial leadership and operational structure as it prepares for a series of anticipated vaccine launches over the next several years. The company expects potential introductions of its mRNA-based seasonal flu vaccine, combined flu/COVID-19 vaccine, and norovirus vaccine between 2027 and 2028. As part of this effort, Moderna has appointed Esther Banque, […]

The post Moderna Commercial Expansion Accelerates Vaccine Launches first appeared on World Pharma Today.

Jazz AbCellera Alliance Targets Next-Generation Cancer Drugs

Yuvraj — Thu, 18 Jun 2026 09:46:59 +0000

Jazz Pharma has entered into a major collaboration with AbCellera focused on advancing cancer immunotherapy programmes, signing an agreement that could ultimately exceed $4 billion in value. Under the arrangement, the companies will work on up to five multispecific antibody-based T-cell engager (TCE) candidates targeting gastrointestinal cancers and other solid tumours. The deal includes an […]

The post Jazz AbCellera Alliance Targets Next-Generation Cancer Drugs first appeared on World Pharma Today.